BIIB vs TDY Comparison

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Teledyne Technologies Inc sells technologies for industrial markets. Roughly a fourth of Teledyne's revenue comes from contracts with the United States government. The firm operates in four segments: instrumentation, digital imaging, aerospace and defense electronics, and engineered systems. The instrumentation segment provides monitoring instruments primarily for marine and environmental applications. The digital imaging segment contributes majority of proportion of revenue and includes image sensors and cameras for industrial, government, and medical customers. The aerospace and defense electronics segment provides electronic components and communication products for aircraft. The engineered systems segment provides solutions for defense, space, environmental, and energy applications.